0GT Stock Chart & Stats
€28.19
€0.74(2.98%)
At close: 4:00 PM EDT
€28.19
€0.74(2.98%)
Day’s Range― - ―
52-Week Range€18.90 - €32.80
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€1.39B
Enterprise Value€1.87B
Total Cash (Recent Filing)€292.82M
Total Debt (Recent Filing)€2.68M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 10, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding64,526,245
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio2.85
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.22Price Target Upside42.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.24
Revenue Forecast (FY)€28.50M
Bulls Say, Bears Say
Bulls Say
Phase III ExecutionCompleting Phase III enrollment ahead of target, while reporting no treatment discontinuations, strengthens execution confidence and preserves statistical power. This advances Stoke toward its pivotal Q3 2027 readout and supports a clearer path to potential regulatory submission.
Long-term Clinical EvidenceLong-term adaptive-functioning improvements, seizure reductions, and sustained treatment exposure provide evidence that the lead program may deliver durable clinical benefits. The absence of new safety signals also supports physician and payer confidence as regulatory discussions progress.
Financial And Manufacturing ReadinessA sizable pro forma cash balance and completed commercial manufacturing validation improve Stoke’s ability to fund development, prepare its CMC submission, and support a potential launch. Together, they reduce near-term operational friction as the company advances toward 2028.
Bears Say
Heavy Losses And Cash BurnLarge TTM operating and net losses indicate that Stoke has not yet established a stable earnings base, while renewed cash burn increases dependence on its available funding. If spending remains elevated, future financing needs could constrain strategic flexibility.
Regulatory And Timing RiskPending agreement with the FDA on statistical methods and endpoint presentation creates regulatory execution risk even after enrollment completion. The extended path to the Q3 2027 readout leaves substantial time for clinical, procedural, or submission delays before approval is possible.
Ex-U.S. Partner DependenceDependence on Biogen for ex-U.S. access means Stoke’s international commercialization pace will partly reflect an external partner’s execution and agreements. This may limit the company’s direct control over geographic rollout, market penetration, and the timing of global revenue.
Stoke Therapeutics News
0GT FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was €18.90 and its highest was €32.80 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Stoke Therapeutics Inc’s market cap is €1.39B.
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 23 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on Aug 03, 2026. The company reported -€0.828 earnings per share for the quarter, missing the consensus estimate of -€0.707 by -€0.12.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate is -0.83.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 64,526,245 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -€0.828 in its last earnings report, missing expectations of -€0.707. Following the earnings report the stock price went up 3.069%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:0GT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€40.22 (42.69% Upside)
€40.22 (42.69% Upside)
Blogger Sentiment
Bullish
DE:0GT Sentiment 60%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.26%
12-Months-Change
Fundamentals
Return on Equity
-59.36%
Trailing 12-Months
Asset Growth
2.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
0GT Company Deck
0GT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivers multiple strong operational and clinical positives: faster-than-expected Phase III enrollment (162 vs target ≥150), 0% discontinuations (vs 15% assumed), robust long-term OLE data (statistically significant Vineland improvements through 4 years, durable seizure reductions), completed manufacturing validation, and a pro forma cash position (~$420M) supporting runway to a potential early-2028 U.S. launch. Key risks are procedural and timing-related rather than clinical safety: SAP and label details are not yet finalized with the FDA, the final Phase III readout and completion of the rolling NDA extend into Q3 2027, inclusion of OLE data in the label is not guaranteed, and diagnosis/access gaps (particularly in adults) and reliance on partner execution outside North America remain challenges. On balance, the positive clinical progress, regulatory preparedness, financial runway, and commercial planning materially outweigh the remaining uncertainties.View all DE:0GT earnings summaries0GT Stock 12 Month Forecast
Average Price Target
€40.22
▲(42.69% Upside)
Technical Analysis
Sarepta Therapeutics
―
uniQure
―
Wave Life Sciences
―
Intellia Therapeutics
―
Taysha Gene Therapies
―